Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol 2015; 21(42): 11984-12002 [PMID: 26576087 DOI: 10.3748/wjg.v21.i42.11984]
Corresponding Author of This Article
Zahra Meshkat, PhD, Antimicrobial Resistance Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran. meshkatz@mums.ac.ir
Research Domain of This Article
Virology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 14, 2015; 21(42): 11984-12002 Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.11984
Progress in the development of vaccines for hepatitis C virus infection
Faezeh Ghasemi, Sina Rostami, Zahra Meshkat
Faezeh Ghasemi, Department of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran
Sina Rostami, Department of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran
Sina Rostami, The Influenza Centre, Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway
Zahra Meshkat, Antimicrobial Resistance Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran
Author contributions: Ghasemi F, Rostami S and Meshkat Z wrote the paper based on the results of published materials; The manuscript was further read and approved by all the authors.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Zahra Meshkat, PhD, Antimicrobial Resistance Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran. meshkatz@mums.ac.ir
Telephone: +98-51-38012453 Fax: +98-51-38002287
Received: April 28, 2015 Peer-review started: May 7, 2015 First decision: June 2, 2015 Revised: July 19, 2015 Accepted: September 14, 2015 Article in press: September 14, 2015 Published online: November 14, 2015 Processing time: 196 Days and 23.2 Hours
Core Tip
Core tip: Chronic hepatitis C virus (HCV) infection occurs in about 75%-90% of acutely infected individuals. It may progress to liver cirrhosis or hepatocellular carcinoma. Despite satisfactory progress in the management and treatment of chronic hepatitis C, it remains one of the most prominent viral infections worldwide. Although no reliable vaccine for it has yet been developed, researchers are trying to design and develop different types of vaccines to prevent HCV infection or to cure the chronic form of the disease. The current article provides an overview of the latest progress in the development of preventive and therapeutic vaccines against HCV infection in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines, and viral vectors expressing HCV genes.